"Impacting cancer research beyond the bench: Play to your strengths and follow your gut"
Date: Wednesday, February 14, 2018 at 12:00pm
Location: 4515 BSRB
Senior Science Writer
Director for Strategic Partnerships
University of Chicago Medicine
Comprehensive Cancer Center
Dr. Goss graduated with a Bachelor’s degree in Chemistry from the College of Wooster (Ohio) and a Ph.D. in Cell Biology from Vanderbilt University. After a postdoctoral fellowship in the Department of Molecular Genetics, Biochemistry and Microbiology at the University of Cincinnati, Dr. Goss started her independent research program at the University of Cincinnati and then moved her laboratory to the University of Chicago in 2007. The major focus of her work has been the molecular events responsible for breast and colorectal tumor initiation and progression, with a particular emphasis on the APC tumor suppressor gene and Wnt signal transduction pathway. Her work has been supported by grants from the American Cancer Society, Susan G. Komen Breast Cancer Foundation, American Association for Cancer Research and National Cancer Institute. Since 2013, she has served as the Senior Science Writer and Director of Strategic Partnerships at the University of Chicago Medicine Comprehensive Cancer Center. In this role, she manages the Comprehensive Cancer Center’s science communications, education, advocacy and outreach efforts.
"Life in a Biotech Startup"
Date: Wednesday, December 6, 2017 at 12:00pm
Location: 4515 BSRB
Manager, Research Operations, ONL Therapeutics
I manage the research projects being performed at ONL Therapeutics and with its collaborators. Broadly speaking, my work involves driving the company's exploration of new drug compounds and new diseases in which to test our compounds. I work closely with our CEO and CSO to outline and execute the company's research goals. I also work with our VP of development to assist in the pre-clinical development of our lead compound in preparation for clinical trials.
"The Transition from Pharma to Academia: Lessons Learned"
Date: Wednesday, November 15, 2017 at 12:00pm"
Location: 3515 BSRB
Research Professor, Department of Radiology and Pharmacology
Co-Director, Developmental Therapeutics Program
Before joining the University of Michigan in 2009, Dr. Sebolt-Leopold was the executive director of the Mechanistic and Target Biology Department at Pfizer Global R&D in Ann Arbor, where she led a group of over 100 scientists dedicated to early stage drug discovery activities, encompassing molecular pharmacology, assay development, and biomarker validation. Now the former Pfizer facility is the University of Michigan North Campus Research Complex, and Dr. Sebolt-Leopold is a principal investigator in TOP, where her laboratory is focused on the design of combination therapies targeting KRAS mutant cancers. Dr. Sebolt-Leopold’s team was recruited by the Center for Molecular Imaging as part of an effort to design and develop small molecules to be used for the early diagnosis of cancer. The therapeutic inhibition of protein kinases has revolutionized the treatment of certain cancers—their diversity and role in cell signaling makes them attractive targets for drug design, and the ability to non-invasively diagnose and molecularly define an individual’s tumor will enable the development of personalized therapies. MEK is a critical component of the RAS-MAP kinase signaling pathway, which is activated in a large percentage of cancers. Dr. Sebolt-Leopold co-chaired the project team that was the first in the pharmaceutical industry to design, synthesize and advance a small molecule MEK kinase inhibitor into the clinic. Dr. Sebolt-Leopold has led multiple cross-disciplinary research teams, resulting in the advancement of clinical candidates, including the MEK inhibitors CI-1040 and PD0325901. These agents entered the clinical arena based on their promising activity in preclinical models, where they effectively block RAS onogenic signaling. The Sebolt-Leopold lab’s success in championing the anticancer drug potential of MEK inhibitors is reflected in the number of pharmaceutical companies subsequently launching research programs around the CI-1040/PD0325901 template. Consequently, there are nearly a dozen MEK inhibitors currently undergoing clinical evaluation.